433 reports of this reaction
3.4% of all SCOPOLAMINE reports
#4 most reported adverse reaction
DIZZINESS is the #4 most commonly reported adverse reaction for SCOPOLAMINE, manufactured by Baxter Healthcare Corporation. There are 433 FDA adverse event reports linking SCOPOLAMINE to DIZZINESS. This represents approximately 3.4% of all 12,807 adverse event reports for this drug.
Patients taking SCOPOLAMINE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among SCOPOLAMINE users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for SCOPOLAMINE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 433 FDA reports for SCOPOLAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.4% of all adverse event reports for SCOPOLAMINE, making it a notable side effect.
If you experience dizziness while taking SCOPOLAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.